Galera Therapeutics Future Growth
Future criteria checks 0/6
Actualmente no disponemos de suficiente cobertura de analistas para prever el crecimiento y los ingresos de Galera Therapeutics.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
Biotechs earnings growth | 20.8% |
Revenue growth rate | n/a |
Future return on equity | n/a |
Analyst coverage | None |
Last updated | n/a |
Recent future growth updates
Recent updates
Galera Therapeutics (NASDAQ:GRTX) Will Have To Spend Its Cash Wisely
Feb 15Galera Therapeutics (NASDAQ:GRTX) Will Have To Spend Its Cash Wisely
Oct 25Galera Therapeutics appoints chief medical officer
Sep 01Galera down ~8% after phase 1 data for non-small cell lung cancer combination treatment
Jun 29Companies Like Galera Therapeutics (NASDAQ:GRTX) Could Be Quite Risky
Jun 15Is Galera Therapeutics Stock A Buy, Sell, Or Hold? Several Catalysts To Watch In 2022
Mar 23Here's Why We're A Bit Worried About Galera Therapeutics' (NASDAQ:GRTX) Cash Burn Situation
Feb 24Galera Therapeutics: Trial Reversal Did Not Take The Stock Higher
Dec 24Companies Like Galera Therapeutics (NASDAQ:GRTX) Could Be Quite Risky
Nov 04Will Galera Therapeutics (NASDAQ:GRTX) Spend Its Cash Wisely?
Aug 05Here's Why We're Watching Galera Therapeutics' (NASDAQ:GRTX) Cash Burn Situation
Feb 17Galera Therapeutics EPS beats by $0.08
Nov 10In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Galera Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2023 | N/A | -59 | -45 | -45 | N/A |
9/30/2023 | N/A | -70 | -49 | -49 | N/A |
6/30/2023 | N/A | -71 | -46 | -46 | N/A |
3/31/2023 | N/A | -64 | -44 | -44 | N/A |
12/31/2022 | N/A | -62 | -43 | -43 | N/A |
9/30/2022 | N/A | -63 | -47 | -47 | N/A |
6/30/2022 | N/A | -69 | -56 | -56 | N/A |
3/31/2022 | N/A | -77 | -64 | -64 | N/A |
12/31/2021 | N/A | -81 | -68 | -68 | N/A |
9/30/2021 | N/A | -84 | -67 | -67 | N/A |
6/30/2021 | N/A | -78 | -64 | -64 | N/A |
3/31/2021 | N/A | -75 | -63 | -62 | N/A |
12/31/2020 | N/A | -74 | -60 | -60 | N/A |
9/30/2020 | N/A | -72 | -59 | -58 | N/A |
6/30/2020 | N/A | -70 | -57 | -56 | N/A |
3/31/2020 | N/A | -65 | -50 | -50 | N/A |
12/31/2019 | N/A | -59 | -47 | -47 | N/A |
9/30/2019 | N/A | -52 | -39 | -38 | N/A |
6/30/2019 | N/A | -43 | -31 | -30 | N/A |
3/31/2019 | N/A | -36 | -26 | -26 | N/A |
12/31/2018 | N/A | -30 | -23 | -22 | N/A |
Analyst Future Growth Forecasts
Ingresos vs. tasa de ahorro: Datos insuficientes para determinar si el crecimiento previsto de los beneficios de GRTX es superior a la tasa de ahorro (2.2%).
Beneficios frente mercado: Datos insuficientes para determinar si se prevé que los beneficios de GRTX crezcan más deprisa que el mercado US
Beneficios de alto crecimiento: Datos insuficientes para determinar si se espera que los beneficios de GRTX crezcan significativamente en los próximos 3 años.
Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de GRTX crezcan más rápido que el mercado de US.
Ingresos de alto crecimiento: No hay datos suficientes para determinar si se prevé que los ingresos de GRTX crezcan a un ritmo superior a 20% al año.
Earnings per Share Growth Forecasts
Future Return on Equity
Futura rentabilidad financiera (ROE): Datos insuficientes para determinar si la Rentabilidad de los fondos propios de GRTX se prevé elevada dentro de 3 años.